AML
Clinical trials for AML explained in plain language.
Never miss a new study
Get alerted when new AML trials appear
Sign up with your email to follow new studies for AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for resistant blood cancer
Disease control OngoingThis study is testing a combination of two drugs, gemtuzumab ozogamicin (GO) and gilteritinib, in adults with a type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The leukemia must have a specific genetic change called FLT3 mutation. The goal i…
Matched conditions: AML
Phase: PHASE2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated May 17, 2026 05:31 UTC
-
New antibody drug aims to wipe out hidden leukemia cells
Disease control OngoingThis study tests an experimental drug called vibecotamab in 42 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose cancer did not fully respond to standard treatments. The drug is designed to help the immune system find and destroy remaining cancer ce…
Matched conditions: AML
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 05:29 UTC
-
New chemo cocktail aims to boost remission in elderly AML patients
Disease control OngoingThis study tests whether a new combination of chemotherapy drugs (HAV) works better than another combo (DAV/IAV) for adults aged 60-75 with acute myeloid leukemia (AML). About 41 participants will receive one of the two treatments to see which leads to longer remission and surviv…
Matched conditions: AML
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New precision therapy aims to intercept AML relapse before it starts
Disease control OngoingThis study tests whether giving targeted drugs early can prevent acute myeloid leukemia (AML) from returning in patients who still have small amounts of cancer cells after initial treatment. It involves 3 participants and focuses on safety and side effects. The approach uses gene…
Matched conditions: AML
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New combo tackles blood cancer relapse after transplant
Disease control OngoingThis study tests a combination of two drugs (venetoclax and azacitidine) plus donor immune cells in people whose MDS or AML came back after a stem cell transplant. The goal is to find the best dose and see if the treatment can control the cancer. About 55 adults with relapsed dis…
Matched conditions: AML
Phase: PHASE1, PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated May 07, 2026 18:39 UTC